Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0019

Congress meeting · Dr. Emiko Olsen

21 Jan 2026 · Phone · Dr. Emiko Olsen, IEO Milano · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0019MI request

Capture insight from this engagement

Location: IEO Milano
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Comparator checkpoint monotherapy

Scientific content used

irAE management guide
VOYAGE-1 pivotal data summary

Questions raised

No questions recorded.

Notes

Congress meeting with thoracic medical oncologist at IEO Milano. Discussed comparator checkpoint monotherapy.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0019

Audit history (0)

All create, update and approval events for this record

No audit events in sample data